Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693197 | 0.87 | SLC6A9 (0.66) | SLC6A9 | |
| SCHEMBL27695772 | 0.85 | SLC6A9 (0.78) | SLC6A9 | |
| SCHEMBL678835 | 0.83 | SLC6A9 (0.64) | SLC6A9 | |
| SCHEMBL1819712 | 0.82 | SLC6A9 (0.59) | SLC6A9 | |
| SCHEMBL1820533 | 0.81 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL677926 | 0.80 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL1821895 | 0.80 | SLC6A9 (0.59) | SLC6A9 | |
| SCHEMBL678833 | 0.79 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL1819479 | 0.79 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL3379441 | 0.77 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269782-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | MERCK, SHARP & DOHME LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2328576-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | Merck Sharp & Dohme Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2010035026-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | MERCK SHARP & DOHME LTD (GB) | 2010-04-01 | — | — | WO | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 31/4885LMNA 4415/4885THRB 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.